BML Capital Management LLC Makes New Investment in Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS)

BML Capital Management LLC purchased a new position in shares of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 42,130 shares of the biotechnology company’s stock, valued at approximately $699,000. Pieris Pharmaceuticals comprises 0.4% of BML Capital Management LLC’s holdings, making the stock its 21st biggest holding. BML Capital Management LLC owned approximately 3.19% of Pieris Pharmaceuticals at the end of the most recent reporting period.

Pieris Pharmaceuticals Trading Down 0.8 %

Shares of NASDAQ:PIRS traded down $0.13 during trading on Tuesday, reaching $15.84. 696 shares of the stock were exchanged, compared to its average volume of 47,524. Pieris Pharmaceuticals, Inc. has a 12 month low of $6.20 and a 12 month high of $22.32. The firm has a market cap of $20.91 million, a PE ratio of -0.85 and a beta of 0.66. The stock has a 50-day moving average price of $16.74 and a 200-day moving average price of $13.65.

Pieris Pharmaceuticals (NASDAQ:PIRS) last issued its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported ($2.76) earnings per share (EPS) for the quarter. Pieris Pharmaceuticals had a negative return on equity of 101.29% and a negative net margin of 39.71%.

Wall Street Analyst Weigh In

Separately, StockNews.com raised Pieris Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday.

Pieris Pharmaceuticals Profile

Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.